South Street Advisors LLC Has $17.84 Million Position in Exelixis, Inc. $EXEL

South Street Advisors LLC decreased its position in Exelixis, Inc. (NASDAQ:EXEL) by 4.5% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 406,909 shares of the biotechnology company’s stock after selling 19,272 shares during the period. Exelixis makes up 2.5% of South Street Advisors LLC’s portfolio, making the stock its 16th largest position. South Street Advisors LLC’s holdings in Exelixis were worth $17,835,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Anchor Investment Management LLC increased its stake in Exelixis by 500.0% during the 3rd quarter. Anchor Investment Management LLC now owns 600 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 500 shares in the last quarter. Activest Wealth Management acquired a new stake in Exelixis during the 4th quarter valued at $32,000. Northwestern Mutual Wealth Management Co. lifted its holdings in Exelixis by 1,380.4% during the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 829 shares of the biotechnology company’s stock valued at $34,000 after purchasing an additional 773 shares during the last quarter. V Square Quantitative Management LLC acquired a new stake in Exelixis during the 4th quarter valued at $44,000. Finally, Abich Financial Wealth Management LLC acquired a new stake in Exelixis during the third quarter worth approximately $47,000. Institutional investors and hedge funds own 85.27% of the company’s stock.

Insider Buying and Selling at Exelixis

In other Exelixis news, EVP Dana Aftab sold 43,451 shares of the business’s stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $50.35, for a total transaction of $2,187,757.85. Following the transaction, the executive vice president directly owned 594,741 shares of the company’s stock, valued at approximately $29,945,209.35. The trade was a 6.81% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Patrick J. Haley sold 32,110 shares of the company’s stock in a transaction dated Wednesday, May 20th. The stock was sold at an average price of $49.81, for a total transaction of $1,599,399.10. Following the completion of the sale, the executive vice president directly owned 357,638 shares in the company, valued at $17,813,948.78. This represents a 8.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 205,433 shares of company stock worth $9,930,259. 2.60% of the stock is owned by corporate insiders.

Key Headlines Impacting Exelixis

Here are the key news stories impacting Exelixis this week:

• Positive Sentiment: Zacks Research raised its Q2 2026 EPS estimate for Exelixis to $0.75 from $0.72, reinforcing expectations that the company can continue delivering solid profitability.
• Positive Sentiment: Exelixis is set to participate in upcoming June investor conferences, which can help keep attention on the stock and provide new updates on pipeline and commercial progress. Article Title
• Positive Sentiment: A recent article argued that profitable, cash-generative biotech names like Exelixis may benefit as investors rotate away from expensive growth stocks and toward defensive healthcare ideas. Article Title
• Positive Sentiment: At the company’s annual meeting, investors backed the board, equity plan, and executive pay, signaling governance support and reducing uncertainty. Article Title
• Neutral Sentiment: Exelixis presented at Bernstein’s Strategic Decisions Conference, which keeps the company visible to institutional investors but did not include any major new operating update. Article Title
• Neutral Sentiment: A short-interest report showed essentially no short interest in Exelixis, suggesting limited bearish positioning but not a meaningful catalyst on its own.
• Negative Sentiment: EVP Dana Aftab sold 43,451 shares at an average price of $50.35, a disclosed insider sale that can weigh on sentiment even though the executive still holds a large position. Article Title

Exelixis Trading Up 2.8%

Shares of Exelixis stock opened at $51.45 on Friday. The company’s 50-day moving average price is $45.83 and its 200-day moving average price is $44.18. The company has a market cap of $12.93 billion, a price-to-earnings ratio of 17.09, a PEG ratio of 1.06 and a beta of 0.38. Exelixis, Inc. has a 12-month low of $33.76 and a 12-month high of $52.96.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported $0.87 EPS for the quarter, topping the consensus estimate of $0.75 by $0.12. The firm had revenue of $610.81 million for the quarter, compared to the consensus estimate of $607.51 million. Exelixis had a net margin of 35.08% and a return on equity of 39.89%. The business’s revenue was up 10.0% compared to the same quarter last year. During the same period last year, the firm posted $0.55 earnings per share. On average, sell-side analysts predict that Exelixis, Inc. will post 3.15 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms recently commented on EXEL. HC Wainwright boosted their price target on Exelixis from $54.00 to $56.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. Wall Street Zen upgraded shares of Exelixis from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Exelixis in a research note on Tuesday, May 19th. Morgan Stanley increased their price objective on Exelixis from $49.00 to $50.00 and gave the company an “equal weight” rating in a report on Wednesday, May 6th. Finally, Zacks Research downgraded shares of Exelixis from a “strong-buy” rating to a “hold” rating in a research report on Thursday, March 5th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, eleven have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, Exelixis has a consensus rating of “Hold” and a consensus price target of $47.35.

About Exelixis

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.